Biciromab
Biciromab
Biciromab (pronounced as bi-ci-ro-mab) is a type of monoclonal antibody used in the field of medicine and biotechnology.
Etymology
The term "Biciromab" is derived from the Latin roots "bi-", meaning two, "ciro", meaning to move around, and "mab", an abbreviation for monoclonal antibody. This refers to the dual action of the antibody in the body.
Definition
Biciromab is a laboratory-produced molecule that's carefully engineered to attach to specific defects in cancer cells. It's part of a class of treatments known as targeted therapy. Biciromab is designed to bind to specific receptors or proteins in the body, which can help the immune system recognize and attack cancer cells.
Related Terms
- Monoclonal Antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. Biciromab is a type of monoclonal antibody.
- Targeted Therapy: A type of cancer treatment that uses drugs or other substances to identify and attack specific types of cancer cells with less harm to normal cells.
- Receptor: A protein molecule in a cell to which mobile signaling molecules may attach. Biciromab is designed to bind to specific receptors in the body.
- Protein: A molecule composed of polymers of amino acids joined together by peptide bonds. Biciromab is a type of protein.
Usage
Biciromab is used in the treatment of various types of cancers. It works by binding to specific receptors on cancer cells, thereby marking them for destruction by the body's immune system.
See Also
External links
- Medical encyclopedia article on Biciromab
- Wikipedia's article - Biciromab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski